Tahir Alper Cinli

Dr. Tahir Alper Cinli

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in International Journal of Hematologic Oncology
Verified
Journal Article
Open access
OYOsman Yokus
Osman Yokus
CHCelalettin Herek
Celalettin Herek
TCTahir Alper Cinli
Tahir Alper Cinli
HGHasan GÖZE
Hasan GÖZE
ISIstemi Serin
Istemi Serin
Background: Recent studies have shown the increased risk of mortality in cases with acute leukemia and iron overload. We aimed to determine the status of iron overload in patients with acute leukem...

23 July 2024 in Cytology and Genetics
Verified
Journal Article
Closed access
PDF file
ISIstemi Serin
Istemi Serin
YOYasemin Oyacı
Yasemin Oyacı
MPMustafa Pehlivan
Mustafa Pehlivan
IDIlknur Demir
Ilknur Demir
BDBurcak Demir
Burcak Demir
SPSacide Pehlivan
Sacide Pehlivan
Leptin is mainly produced from adipose tissue and released into the circulation. Circulating leptin binds to the leptin receptor (LEPR) in the brain, which

1 October 2026 in Experimental Biomedical Research
Verified
Journal Article
Open access
PDF file
HGHasan GÖZE
Hasan GÖZE
TETuna Eren Esen
Tuna Eren Esen
IYİsa Yalçınkaya
İsa Yalçınkaya
GBGökhan Burul
Gökhan Burul
TCTahir Alper Cinli
Tahir Alper Cinli
ISİstemi Serin
İstemi Serin
Aim: To determine whether next-generation sequencing (NGS) improves 2022 European LeukemiaNet (ELN) risk stratification by identifying myelodysplasia-related (MDS-related) mutations in acute myeloid leukemia (AML). Methods: We analyzed 111 consecutive adults with newly diagnosed non-promyelocytic acute myeloid leukemia (AML) who underwent diagnostic NGS with a myeloid gene panel. For each patient, an ELN 2022 risk category was assigned using four diagnostic modalities—metaphase karyotyping, fluorescence in situ hybridization (FISH), targeted molecular (PCR) testing, and NGS. A conventional category was defined as the most adverse assignment obtained from karyotyping, FISH, and PCR, whereas the NGS-inclusive category was defined as the most adverse assignment obtained when NGS was added to these modalities. The primary outcome was within-patient reclassification attributable to the incorporation of NGS. Reporting followed the STROBE guidelines. Results: The median age was 56 years, and 65.8% of patients were male. The most frequently mutated genes were FLT3 (25.2%), NPM1 (19.8%), TET2 (17.1%), TP53 (16.2%), and RUNX1 (16.2%); 38.7% of patients harbored at least one MDS-related mutation. Among the 110 patients with both classifications available, incorporation of NGS upgraded the ELN 2022 category in 33 patients (30.0%; 95% CI, 22.2–39.1)—29 from intermediate and 4 from favorable to adverse—with no downgrades. The proportion of patients classified as adverse risk more than doubled, from 30 (27.3%) to 63 (57.3%) (McNemar p < 0.001). Upgrades were driven predominantly by MDS-related mutations: 29 of 33 upgraded patients (87.9%) carried at least one such mutation, most commonly in ASXL1 (45.5%), RUNX1 (39.4%), SRSF2 (30.3%), or STAG2 (24.2%). Conclusions: Even among patients selected for NGS testing, an ELN 2022 category based on conventional cytogenetic and PCR testing alone was inaccurate, almost invariably too favorable, in approximately one in three patients, and no clinical feature reliably identified them. NGS is therefore indispensable for accurate risk stratification in AML.


Verified
Journal Article
Open access
PDF file
TCTahir Alper Cinli
Tahir Alper Cinli
GBGÖKHAN BURUL
GÖKHAN BURUL
HGHasan GÖZE
Hasan GÖZE
MAMesut Ayer
Mesut Ayer
ISIstemi Serin
Istemi Serin
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Despite advances in immunochemotherapy, approximately 30–40% of patients experience relapsed or refractory disease. Nutritional and inflammatory status, reflected by composite indices, may independently influence clinical outcomes. However, the prognostic value of the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), and Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) score has not been well established in DLBCL patients treated with rituximab-based regimens. Methods: We retrospectively analyzed 192 patients with newly diagnosed DLBCL who received at least three cycles of R-CHOP or R-EPOCH at Başakşehir Çam and Sakura City Hospital between January 2020 and January 2026. Receiver operating characteristic (ROC) curve analysis was performed to determine optimal cutoff values. Kaplan–Meier analysis with log-rank testing and univariable/multivariable Cox proportional hazards regression analyses were used to evaluate the prognostic impact of the PNI, GNRI, and HALP on overall survival (OS) and progression-free survival (PFS). Results: Among the six indices evaluated (PNI, GNRI, HALP, SII, ALI, and CAR), the PNI demonstrated the highest discriminatory ability for OS (AUC = 0.734, p = 0.001), followed by the HALP (AUC = 0.671, p = 0.020) and GNRI (AUC = 0.668, p = 0.022). The optimal cutoff values were ≤46.45 for the PNI, ≤46.91 for the GNRI, and ≤223.95 for HALP. Low values of all three indices were significantly associated with elevated LDH levels, advanced Ann Arbor stage, and higher IPI category. Kaplan–Meier analysis demonstrated significantly inferior OS in the low PNI (52.8 ± 2.6 vs. 67.1 ± 1.2 months, p = 0.001), low GNRI (49.5 ± 3.1 vs. 66.0 ± 1.4 months, p = 0.001), and low HALP (58.8 ± 2.8 vs. 64.9 ± 1.2 months, p = 0.005) groups. In separate multivariable Cox models adjusted for sex and IPI, the PNI (HR = 0.216, p = 0.009), HALP (HR = 0.276, p = 0.031), and GNRI (HR = 0.294, p = 0.011) remained independently associated with OS. No significant association was observed between these indices and PFS. Conclusions: The PNI, GNRI, and HALP are independent prognostic markers in patients with DLBCL treated with rituximab-based regimens. These readily available and inexpensive baseline indices may complement the IPI in identifying patients at higher risk of adverse outcomes and support risk stratification at diagnosis.

14 September 2026 in CAM and Sakura Medical Journal
Verified
Journal Article
Open access
PDF file
TCTahir Alper Cinli
Tahir Alper Cinli
Ibrutinib-Associated Kaposi Sarcoma and Reversible Renal Manifestation in Chronic Lymphocytic Leukemia - Cam & Sakura Medical Journal